As horsepox virus may have been accidentally extirpated there has most likely been no previous exposure to the vector, and any vaccine administered based on it is unlikely to encounter already-present neutralising antibodies.
Tonix Pharmaceuticals has expanded its ongoing partnership with non-profit Southern Research to study T-cell immune responses to SARS-CoV-2, the novel coronavirus that causes Covid-19.
Tonix Pharmaceuticals has signed a research collaboration and exclusive licensing agreement with the University of Alberta in Canada for three new vaccine candidates to prevent Covid-19.